Discover Novel Targets and Applications with Tempus EXPLORE

Discover how Leap Therapeutics enhanced their understanding of a key biomarker for their clinical program in just a few months with Tempus EXPLORE, a cost-efficient research tool that provides access to the Tempus oncology database via Tempus bioinformatics experts. Watch replay from 9/30/2021.

Characterization of KRAS Mutation Variants and Prevalence of KRAS-G12C in Gastrointestinal Malignancies

Tempus-authored, Annals of Oncology —  Background The KRAS G12C inhibitor sotorasib has shown promising anticancer activity in patients with advanced solid tumors harboring the KRAS G12C mutation, holding the potential for transforming clinical management of KRAS mutated solid tumors. The distribution of KRAS variants, including G12C in gastrointestinal (GI) cancers, has not been well described. Herein, … Continued

Study Confirms That Americans Neglected Their Healthcare During COVID-19 Pandemic

From the beginning of the pandemic, health experts were concerned that millions of Americans would defer treatment of existing illnesses—including cancer—and postpone routine preventative screenings given the justifiable fear of contracting COVID-19. Now, more than a year after COVID-19 forced the country to a complete halt, a clearer picture is starting to emerge surrounding Americans’ … Continued

Bayer and Tempus Initiate Collaboration to Advance Patient Access to Genomic Testing and Precision Medicine

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Tempus xT broad-panel genomic sequencing … Continued